Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway and Neuroscience Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for WWC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WWC1 Full-Length & WW Domain Recombinant Protein; High purity (>95%), Endotoxin <1EU/µg. HEK293 Expressed. Sequence Verified. | View WWC1 Products |
| Mutant Panel | WWC1 Ser/Thr Phosphomimetic Mutants (S525D, etc.); Critical for LATS1/2 binding studies. | View WWC1 Products |
| Gene Delivery | WWC1 Promise-ORF / Lentivirus; Full-length ORF with C-terminal tags for stable cell line construction. | View WWC1 Products |
| Benchmark Ab | Anti-WWC1 (KIBRA) Recombinant Antibody; Positive control for Western Blot, IP, IHC. | View WWC1 Products |
| Validator | WWC1 siRNA Set (3 target-specific sequences); For knockdown verification and specificity controls. | View WWC1 Products |
| Related Target: YAP1 | YAP1 (Downstream transcription factor); Reporter gene assays for pathway modulation. | View YAP1 Products |
| Related Target: LATS1 | LATS1 Kinase (Hippo pathway effector); Direct WWC1 binding partner; co-IP assay essential. | View LATS1 Products |
| Related Target: NF2 | NF2/Merlin (Upstream regulator); Scaffold interaction node with WWC1. | View NF2 Products |
| Related Target: WWC2 | WWC2 (Paralog); For subfamily off-target counter-screening and selectivity assays. | View WWC2 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Screening (e.g., WWC1-LATS1) | High-purity recombinant proteins with Theoretical MW precisely verified by Mass Spec. |
| Scaffold Complex Assembly (Ternary with NF2) | Co-expression ready: WWC1 + NF2 + SAV1 protein bundles available. |
| Phosphorylation State Dependence | Phosphomimetic (S525D) and phosphodeficient (S525A) mutants with verified mass spec. |
| Subcellular Localization Studies | Lentivirus particles with fluorescent tags (mCherry/GFP) for live-cell imaging. |
| Domain-specific PPI mapping (WW vs. C2) | Domain-truncated mutants (ΔWW, ΔC2) with N-/C-terminal tags, Sequence Verified by Mass Spec. |
| Cross-species translation (human to mouse) | Human and Mouse WWC1 ortholog proteins available, HEK293 expressed, >95% purity. |
| Lack of Controls | Recombinant anti-WWC1 and benchmark-grade antibodies included for assay standardization. |
| False Positives in Binding Assays | Validated siRNA included for specificity checks; Empty vector controls. |
Live WWC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The WWC1 (KIBRA) target represents an emerging node in the Hippo signaling cascade, positioning it as a critical scaffold for next-generation cancer therapeutics and regenerative medicine. Unlike traditional kinase targets, WWC1 functions as a protein-protein interaction (PPI) hub, connecting NF2/Merlin to LATS1/2 kinases. Current R&D is shifting from genetic validation toward small molecule PPI stabilization/disruption strategies, particularly for cancers with NF2 mutations (mesothelioma, schwannoma) and for kidney-related indications where WWC1 polymorphisms predict disease progression. In neuroscience, WWC1 regulates AMPA receptor trafficking, positioning it as a pivotal target for Alzheimer's disease and memory disorders. As first-generation Hippo pathway inhibitors targeting MST1/2 face toxicity limitations, the industry is pivoting to scaffold proteins like WWC1 that offer greater tissue specificity. The next wave of R&D focuses on allosteric activators that enhance WWC1-LATS1/2 complex formation to suppress YAP/TAZ oncogenic activity, as well as gene therapy approaches to restore WWC1 expression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Stabilizer | AstraZeneca, Vertex, Academic Consortia | NF2-mutant Cancers, Mesothelioma, Solid Tumors | Ternary Complex Formation (WWC1-LATS1-NF2); Need high-purity full-length scaffold proteins |
| Peptide Disruptor (WW Domain) | Academic Consortia | Solid Tumors, Synaptic Plasticity Disorders | Competitive Binding Assay (AlphaScreen/SPR); Need purified WW domain fragments |
| Gene Therapy (AAV/Lenti) | Academic Spin-offs, Neurology Biotechs | Alzheimer's Disease, Memory Loss, Acute Kidney Injury | Cell Line Construction (High-titer Lentivirus for stable expression models) |
| Targeted Protein Degradation (PROTAC/Molecular Glue) | Frontier Research, Emerging Biotech | YAP-hyperactive Cancers, Refractory Carcinoma | Intracellular Localization Assay (Tagged lentivirus constructs); Need high-purity scaffold proteins |